Related Experiment Video
Updated: Apr 21, 2026
12:13
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
7.3K
Interplay between ADP-Ribosylation and Androgen Receptor Function in Prostate Cancer
Gali Sri Venkata Sai Rishma Reddy1, Krishna Samanta2, Pulak Kar1
1Department of Biological Sciences, SRM University-AP, Amaravati, 522240, India.
Current Pharmaceutical Design
|April 20, 2026
Summary
Poly (ADP-ribose) polymerase (PARP) enzymes regulate androgen receptor (AR) signaling in prostate cancer. Understanding AR-PARP interactions may improve PARP inhibitor and AR inhibitor combinations for advanced prostate cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Androgen receptor (AR) signaling is crucial for prostate physiology and cancer progression.
- Poly (ADP-ribose) polymerase (PARP) mediated ADP-ribosylation is a key regulator of AR activity.
- PARP inhibitors (PARPi) are effective for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
Purpose of the Study:
- To review the interplay between ADP-ribosylation and AR signaling in prostate cancer.
- To emphasize the roles of distinct PARP enzymes in AR activity and therapeutic response.
- To discuss the potential of this regulatory network for future advanced prostate cancer therapies.
Main Methods:
- Review of current knowledge on AR signaling and ADP-ribosylation.
- Focus on the roles of PARP7, PARP9/DTX3L, and PARP enzymes.
- Analysis of MARylation and PARylation in prostate tumorigenesis.
Main Results:
- PARP7 and PARP9/DTX3L directly modulate AR function and gene expression.
- PARP enzymes regulate AR via MARylation and PARylation, impacting AR-PARP crosstalk.
- Clinical trials show promise in combining PARPi with AR signaling inhibitors, but efficacy in non-HRR mutated tumors is unclear.
Conclusions:
- The complex interplay between ADP-ribosylation and AR signaling is central to prostate cancer.
- Targeting AR-PARP crosstalk offers potential for novel therapeutic strategies.
- Further research may lead to improved combination therapies benefiting more prostate cancer patients.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
5.2K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.2K
01:22PI3K/mTOR/AKT Signaling Pathway
6.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.5K
01:31Adrenergic Receptors: ɑ Subtype
3.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.4K
01:09GPCRs Regulate Adenylyl Cylase Activity
8.4K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.4K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
01:19Interactions Between Signaling Pathways
8.0K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K